A phase I/II trial of rAd/ p53 (SCH 58500) gene replacement in recurrent ovarian cancer
作者： Richard E Buller , Ingo B Runnebaum , Beth Y Karlan , Jo Ann Horowitz , Mark Shahin
关键词:
摘要: … to SCH 58500 alone and in combination with chemotherapy, (b) to … accessible to laparoscopic or percutaneous biopsy. A … One individual with liver metastasis and progressive disease …
nature.com
sci-hub.se 
researchgate.net 参考文章(74)
L L Nielsen, D C Maneval, P53 tumor suppressor gene therapy for cancer. Cancer Gene Therapy. ,vol. 5, pp. 52- 63 ,(1998)
Jordan U. Gutterman, Kalpana Mujoo, Scott C. Anderson, Daniel C. Maneval, Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma. Oncogene. ,vol. 12, pp. 1617- 1623 ,(1996)
裕一 市瀬, 12) Swisher, Roth, Nemunaitis, et al. Adenovirusmediated p53 gene transfer in advanced nonsmall-cell lung cancer. J Natl Cancer Inst. 1999; 91: 763-71 The journal of the Japan Society for Bronchology. ,vol. 23, pp. 180- ,(2001)
D S Hawkins, G W Demers, D A Galloway, Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Research. ,vol. 56, pp. 892- 898 ,(1996)
Griffiths Ct, Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. National Cancer Institute monograph. ,vol. 42, pp. 101- 104 ,(1975)
Mary M. Hitt, Christina L. Addison, Frank L. Graham, Human adenovirus vectors for gene transfer into mammalian cells. Advances in pharmacology. ,vol. 40, pp. 137- 206 ,(1997) , 10.1016/S1054-3589(08)60140-4
Donald W. Cockcroft, Henry Gault, Prediction of Creatinine Clearance from Serum Creatinine Nephron. ,vol. 16, pp. 31- 41 ,(1976) , 10.1159/000180580
Arthur I. Sagalowsky, M. Craig Hall, Jeffrey M. Bergelson, Zhi Wang, Yingming Li, Jer Tsong Hsieh, Rey Chen Pong, Ching Ping Tseng, Loss of Adenoviral Receptor Expression in Human Bladder Cancer Cells: A Potential Impact on the Efficacy of Gene Therapy Cancer Research. ,vol. 59, pp. 325- 330 ,(1999)
Sheryl Redlin-Frazier, Patrice S. Obermiller, Jeffrey T. Holt, Allison R. Hatmaker, David L. Tait, Ovarian cancer BRCA1 gene therapy: Phase I and II trial differences in immune response and vector stability. Clinical Cancer Research. ,vol. 5, pp. 1708- 1714 ,(1999)
G J Rustin, J N Gennings, A E Nelstrop, H Covarrubias, H E Lambert, K D Bagshawe, Use of CA-125 to predict survival of patients with ovarian carcinoma. North Thames Cooperative Group. Journal of Clinical Oncology. ,vol. 7, pp. 1667- 1671 ,(1989) , 10.1200/JCO.1989.7.11.1667